CSIMarket
 


Immuron Limited  (IMRN)
Other Ticker:  
 

Immuron Limited's Working Capital Ratio

IMRN's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




IMRN Working Capital Ratio (Jun 30 2021)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Jun 30 2020)
IV. Quarter
Y / Y Current Liabilities Change 117.25 % 117.25 % 117.25 % 117.25 % -56.8 %
Y / Y Current Assets Change 484.09 % 484.09 % 484.09 % 484.09 % -34.02 %
Working Capital Ratio MRQ 22.95 22.95 22.95 22.95 8.54
Overall Ranking # # # # # 373
Seq. Current Liabilities Change 0 % 0 % 0 % 117.25 % 0 %
Seq. Current Assets Change 0 % 0 % 0 % 484.09 % 0 %



Working Capital Ratio forth quarter 2021 Comment
Regardless of the sequential decrease in Current Liabilities, Working Capital Ratio detoriated to 22.95 below company average Working Capital Ratio.

Within Major Pharmaceutical Preparations industry Immuron Limited booked the highest Working Capital Ratio than Immuron Limited in the forth quarter 2021. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is IMRN most successful ?
Working Capital Ratio IMRN on the trailing twelve month basis
Working Capital Ratio forth quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market # 0


Working Capital Ratio Statistics
High Average Low
22.95 11.46 5.59
(Jun 30 2021)   (Jun 30 2019)




Financial Statements
Immuron Limited's Current Liabilities $ 1 Millions Visit IMRN's Balance sheet
Immuron Limited's Current Assets $ 26 Millions Visit IMRN's Balance sheet
Source of IMRN's Sales Visit IMRN's Sales by Geography


Cumulative Immuron Limited's Working Capital Ratio

IMRN's Working Capital Ratio for the trailling 12 Months

IMRN Working Capital Ratio

(Jun 30 2021)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Jun 30 2020)
IV. Quarter
Y / Y Current Liabilities TTM Growth 117.25 % 117.25 % 117.25 % 117.25 % -56.8 %
Y / Y Current Assets TTM Growth 484.09 % 484.09 % 484.09 % 484.09 % -34.02 %
Working Capital Ratio TTM 22.95 21.04 18.41 14.59 8.54
Total Ranking TTM # 128 # 128 # 0 # 0 # 0
Seq. Current Liabilities TTM Growth 0 % 0 % 0 % 117.25 % 0 %
Seq. Current Assets TTM Growth 0 % 0 % 0 % 484.09 % 0 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis IMRN Current Assets average more than doubled by 484.09 % in IV. Quarter year on year, faster than Current Liabilities, this led to increase in in Immuron Limited's Working Capital Ratio to 22.95, Working Capital Ratio remained below IMRN average.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 26 other companies have achieved higher Working Capital Ratio than Immuron Limited. While overall ranking remained unchanged compare to previous quarter at no. 128.

Explain Working Capital Ratio
Where is IMRN most successful ?
Working Capital Ratio IMRN on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 27
Healthcare Sector # 48
Within the Market # 128


TTM Working Capital Ratio Statistics
High Average Low
22.96 12.36 5.59
(Jun 30 2021)   (Jun 30 2019)




Companies with similar Working Capital Ratio in the quarter ending Jun 30 2021, within Major Pharmaceutical Preparations Industry Working Capital RatioJun 30 2021 MRQ Current AssetsJun 30 2021 MRQ Current Liabilities
Cassava Sciences Inc   60.29 $ 279.558  Millions$ 4.637  Millions
Nanoviricides inc   59.32 $ 20.827  Millions$ 0.351  Millions
Karuna Therapeutics Inc   55.01 $ 567.098  Millions$ 10.309  Millions
Vaccitech Plc  54.82 $ 256.728  Millions$ 4.683  Millions
Geovax Labs Inc   54.78 $ 19.668  Millions$ 0.359  Millions
Spruce Biosciences Inc   53.39 $ 111.369  Millions$ 2.086  Millions
Lexaria Bioscience Corp   53.01 $ 9.686  Millions$ 0.183  Millions
Strongbridge Biopharma plc  52.21 $ 70.122  Millions$ 1.343  Millions
Reneo Pharmaceuticals Inc   51.30 $ 171.141  Millions$ 3.336  Millions
Verve Therapeutics Inc   48.51 $ 419.564  Millions$ 8.649  Millions
Kyto Technology And Life Science Inc   47.11 $ 8.622  Millions$ 0.183  Millions
Statera Biopharma Inc fka Cytocom Inc   45.98 $ 13.824  Millions$ 0.301  Millions
Genprex Inc   45.90 $ 48.062  Millions$ 1.047  Millions
Edgewise Therapeutics inc.  44.96 $ 302.969  Millions$ 6.739  Millions
Janux Therapeutics Inc   43.09 $ 396.608  Millions$ 9.205  Millions
Pmv Pharmaceuticals Inc   43.05 $ 323.080  Millions$ 7.504  Millions
Synaptogenix Inc   42.78 $ 32.940  Millions$ 0.770  Millions
Arena Pharmaceuticals Inc   42.30 $ 990.435  Millions$ 23.417  Millions
Sensei Biotherapeutics Inc   42.22 $ 165.613  Millions$ 3.923  Millions
Biomea Fusion Inc   40.57 $ 200.521  Millions$ 4.942  Millions
Olema Pharmaceuticals inc   39.39 $ 320.854  Millions$ 8.146  Millions
Eledon Pharmaceuticals Inc   38.32 $ 102.582  Millions$ 2.677  Millions
Nighthawk Biosciences inc   37.22 $ 124.759  Millions$ 3.352  Millions
Longboard Pharmaceuticals Inc   36.87 $ 120.689  Millions$ 3.273  Millions
Tff Pharmaceuticals Inc   36.75 $ 55.457  Millions$ 1.509  Millions
Theriva Biologics inc   36.05 $ 75.632  Millions$ 2.098  Millions
Aldeyra Therapeutics Inc   35.15 $ 256.261  Millions$ 7.291  Millions
Astria Therapeutics inc   35.12 $ 140.052  Millions$ 3.988  Millions
Kalvista Pharmaceuticals Inc   34.10 $ 249.782  Millions$ 7.324  Millions
Agios Pharmaceuticals Inc   33.46 $ 1,702.562  Millions$ 50.878  Millions

Date modified: 2022-09-10T12:54:21+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

RCII's Profile

Stock Price

RCII's Financials

Business Description

Fundamentals

Charts & Quotes

RCII's News

Suppliers

RCII's Competitors

Customers & Markets

Economic Indicators

RCII's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071